Literature DB >> 31602245

Feasibility of low-dose infusion of alteplase for unsuccessful thrombolysis with urokinase in deep venous thrombosis.

Maofeng Gong1, Boxiang Zhao1, Xu He1, Jianping Gu1, Guoping Chen1.   

Abstract

The aim of the present study was to investigate whether the rescue of thrombolysis with the recombinant tissue plasminogen activator (rt-PA) alteplase was an effective and safe therapeutic option in patients who did not respond to urokinase. Between February 2016 and February 2017, 26 patients with deep venous thrombosis (DVT) underwent rescue thrombolysis with alteplase. Unsuccessful thrombolysis with urokinase was defined as a lack of improvement in the degree of thrombotic removal with a lysis rate <50% under one of the following three conditions: Two consecutive venography procedures, administration of >3 million units of total urokinase, or >7 days infusion duration. The thrombus score, lysis rate and post-thrombolysis safety of alteplase, following unsuccessful urokinase thrombolysis were all evaluated. At the end of the unsuccessful urokinase thrombolytic therapy, the mean duration of the perfusion was 6.09±1.60 days, and the mean total dose was (362.5±90.0) ×104 units. No significant difference was detected in the total thrombus score before (7.85±2.40) and at the completion (6.19±2.33) of urokinase thrombolysis (P>0.05). The mean duration of perfusion was 3.36±1.69 days, and the mean total infusion dose was 44.8±22.6 mg for the rescue thrombolysis with alteplase. The mean thrombus score decreased to 1.19±2.10 at the completion of rescue thrombolysis. The alteplase post-thrombolysis scores were significantly decreased compared with those of urokinase thrombolysis (P<0.05). There were 23 (88.5%) patients who achieved a successful lysis rate (grade II/III) following rescue thrombolysis with alteplase, and symptoms of swelling and pain in the affected limbs were significantly improved. Successful thrombolysis rates in patients in the acute (<14 days) and subacute (14-28 days) phases were high (93.3 and 81.8%, respectively; P>0.05). No symptomatic pulmonary embolism or major bleeding occurred during rescue thrombolysis, but minor bleeding complications occurred in 4 cases (15.4%). In conclusion, rescue thrombolysis with alteplase led to an effective and safe outcome in patients with DVT who did not respond to initial thrombolysis with urokinase, and may be a valid and easy alternative treatment option.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  alteplase; catheter- directed thrombolysis; urokinase; venous thrombosis

Year:  2019        PMID: 31602245      PMCID: PMC6777307          DOI: 10.3892/etm.2019.7938

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  21 in total

1.  A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.

Authors:  H Decousus; A Leizorovicz; F Parent; Y Page; B Tardy; P Girard; S Laporte; R Faivre; B Charbonnier; F G Barral; Y Huet; G Simonneau
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

Review 2.  Recombinant tissue plasminogen activators (rtPA): a review.

Authors:  P Gurman; O R Miranda; A Nathan; C Washington; Y Rosen; N M Elman
Journal:  Clin Pharmacol Ther       Date:  2015-01-31       Impact factor: 6.875

3.  Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry.

Authors:  M W Mewissen; G R Seabrook; M H Meissner; J Cynamon; N Labropoulos; S H Haughton
Journal:  Radiology       Date:  1999-04       Impact factor: 11.105

4.  Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial.

Authors:  Susan R Kahn; Stan Shapiro; Philip S Wells; Marc A Rodger; Michael J Kovacs; David R Anderson; Vicky Tagalakis; Adrielle H Houweling; Thierry Ducruet; Christina Holcroft; Mira Johri; Susan Solymoss; Marie-José Miron; Erik Yeo; Reginald Smith; Sam Schulman; Jeannine Kassis; Clive Kearon; Isabelle Chagnon; Turnly Wong; Christine Demers; Rajendar Hanmiah; Scott Kaatz; Rita Selby; Suman Rathbun; Sylvie Desmarais; Lucie Opatrny; Thomas L Ortel; Jeffrey S Ginsberg
Journal:  Lancet       Date:  2013-12-06       Impact factor: 79.321

5.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

Review 6.  Thrombolysis for acute deep vein thrombosis.

Authors:  Lorna Watson; Cathryn Broderick; Matthew P Armon
Journal:  Cochrane Database Syst Rev       Date:  2016-11-10

7.  Anticoagulation period in idiopathic venous thromboembolism. How long is enough?

Authors:  Rami S Farraj
Journal:  Saudi Med J       Date:  2004-07       Impact factor: 1.484

Review 8.  Natural history of venous thromboembolism.

Authors:  Clive Kearon
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

9.  Determinants of early and long-term efficacy of catheter-directed thrombolysis in proximal deep vein thrombosis.

Authors:  Ylva Haig; Tone Enden; Carl-Erik Slagsvold; Leiv Sandvik; Per Morten Sandset; Nils Einar Kløw
Journal:  J Vasc Interv Radiol       Date:  2012-11-22       Impact factor: 3.464

Review 10.  Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism.

Authors:  Suresh Vedantham; Gregory Piazza; Akhilesh K Sista; Neil A Goldenberg
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

View more
  1 in total

1.  Rescue catheter-based therapies for the treatment of acute massive pulmonary embolism after unsuccessful systemic thrombolysis.

Authors:  Maofeng Gong; Guoping Chen; Boxiang Zhao; Jie Kong; Jianping Gu; Xu He
Journal:  J Thromb Thrombolysis       Date:  2021-04       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.